Drug intelligence / Profile preview

STC101

Development stage: Unknown
Lead developer: STC Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STC101 is a biosimilar version of a monoclonal antibody developed by STC Biologics for the treatment of cancer. Its development has been supported by a $2.5 million Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) and a $2 million cash infusion from Ligacept LLC. The funding is intended to facilitate manufacturing scale-up and the initiation of clinical activities. The Massachusetts Life Sciences Center (MLSC) also supported STC Biologics' application for this funding.

Targets

C/EBPβ (CCAAT/enhancer-binding protein beta)C/EBPβ–ATF5 (CCAAT/enhancer-binding protein beta–Activating transcription factor 5 heterodimerization interface (C/EBPβ–ATF5 interface))

Beyond the preview

Go deeper on STC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC101.

Explore the full profile